Idioma:

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Heath, Paul T ; Galiza, Eva P ; Baxter, David N ; Boffito, Marta ; Browne, Duncan ; Burns, Fiona ; Chadwick, David R ; Clark, Rebecca ; Cosgrove, Catherine ; Galloway, James ; Goodman, Anna L ; Heer, Amardeep ; Higham, Andrew ; Iyengar, Shalini ; Jamal, Arham ; Jeanes, Christopher ; Kalra, Philip A ; Kyriakidou, Christina ; McAuley, Daniel F ; Meyrick, Agnieszka ; Minassian, Angela M ; Minton, Jane ; Moore, Patrick ; Munsoor, Imrozia ; Nicholls, Helen ; Osanlou, Orod ; Packham, Jonathan ; Pretswell, Carol H ; San Francisco Ramos, Alberto ; Saralaya, Dinesh ; Sheridan, Ray P ; Smith, Richard ; Soiza, Roy L ; Swift, Pauline A ; Thomson, Emma C ; Turner, Jeremy ; Viljoen, Marianne E ; Albert, Gary ; Cho, Iksung ; Dubovsky, Filip ; Glenn, Greg ; Rivers, Joy ; Robertson, Andreana ; Smith, Kathy ; Toback, Seth

The New England journal of medicine, 2021-09, Vol.385 (13), p.1172-1183 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Autor: Heath, Paul T ; Galiza, Eva P ; Baxter, David N ; Boffito, Marta ; Browne, Duncan ; Burns, Fiona ; Chadwick, David R ; Clark, Rebecca ; Cosgrove, Catherine ; Galloway, James ; Goodman, Anna L ; Heer, Amardeep ; Higham, Andrew ; Iyengar, Shalini ; Jamal, Arham ; Jeanes, Christopher ; Kalra, Philip A ; Kyriakidou, Christina ; McAuley, Daniel F ; Meyrick, Agnieszka ; Minassian, Angela M ; Minton, Jane ; Moore, Patrick ; Munsoor, Imrozia ; Nicholls, Helen ; Osanlou, Orod ; Packham, Jonathan ; Pretswell, Carol H ; San Francisco Ramos, Alberto ; Saralaya, Dinesh ; Sheridan, Ray P ; Smith, Richard ; Soiza, Roy L ; Swift, Pauline A ; Thomson, Emma C ; Turner, Jeremy ; Viljoen, Marianne E ; Albert, Gary ; Cho, Iksung ; Dubovsky, Filip ; Glenn, Greg ; Rivers, Joy ; Robertson, Andreana ; Smith, Kathy ; Toback, Seth
Assuntos: Adolescent ; Adult ; Adverse events ; Aged ; Aged, 80 and over ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Disease transmission ; Humans ; Hypotheses ; Immune response ; Immunogenicity ; Immunogenicity, Vaccine ; Infections ; Infectious Disease ; Influenza ; Injection ; Injections, Intramuscular - adverse effects ; Medical research ; Medicine, Experimental ; Middle Aged ; Nanoparticles ; Original ; Pandemics ; Placebos ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Single-Blind Method ; Spike glycoprotein ; Statistical analysis ; Vaccine efficacy ; Vaccines ; Vaccines, Synthetic - immunology ; Young Adult
É parte de: The New England journal of medicine, 2021-09, Vol.385 (13), p.1172-1183
Notas: The members of the 2019nCoV-302 Study Group are listed in the Supplementary Appendix, available at NEJM.org.
Descrição: In a phase 3 trial involving more than 15,000 participants, two doses of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, administered 21 days apart had a vaccine efficacy of 89.7%. Reactogenicity was generally mild and transient, and adverse events were infrequent and of low grade.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.